Patricia A. Cronin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patricia A. Cronin has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Barbara A. Pockaj
Division of Surgical Oncology and Endocrine Surgery, Mayo Clinic, Phoenix, AZ
4 shared publications- Barbara A. Pockaj
Division of Surgical Oncology, Department of General Surgery, Mayo Clinic Arizona, Phoenix, USA
3 shared publications Esteban Calderon
Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ
3 shared publicationsGeoffrey B. Thompson
Department of Surgery, Mayo Clinic, Rochester, Minnesota
3 shared publicationsHeidi E. Kosiorek
Department of Research, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ
3 shared publicationsHeidi Kosiorek
Department of Research and Biostatistics, Mayo Clinic in Arizona, USA
3 shared publications
Latest Publications
- 1 January 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 245, 107-114
Optimizing Opioid-Prescribing Practices After Parathyroidectomy
- 1 January 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 245, 107-114
Optimizing Opioid-Prescribing Practices After Parathyroidectomy
- 17 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (2) , 395-400
The effects of body mass index on operative time and outcomes in nipple-sparing mastectomy
- 17 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (2) , 395-400
The effects of body mass index on operative time and outcomes in nipple-sparing mastectomy
- 1 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 218 (6) , 1040-1045
Making an informed choice: Which breast reconstruction type has the lowest complication rate?
- 1 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 218 (6) , 1040-1045
Making an informed choice: Which breast reconstruction type has the lowest complication rate?
- 1 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 218 (6) , 1229-1233
Are we choosing wisely in elderly females with breast cancer?
- 1 December 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 218 (6) , 1229-1233
Are we choosing wisely in elderly females with breast cancer?
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , S39-S40
Presentation and Clinical Outcomes in Elderly Women with Breast Cancer Based on Molecular Subtypes
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , S39-S40
Presentation and Clinical Outcomes in Elderly Women with Breast Cancer Based on Molecular Subtypes
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E50
Capsular Contracture after Radiation Therapy Following Mastectomy and Implant-Based Reconstruction
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E50
Capsular Contracture after Radiation Therapy Following Mastectomy and Implant-Based Reconstruction
- Top Cited Papers
- 7 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (504)
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 104 and 3 in 105, respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analyzed up to 115 mutations per patient in 80 plasma samples from 33 women with stage I to III breast cancer. Before treatment, TARDIS detected ctDNA in all patients with 0.11% median AF. After completion of neoadjuvant therapy, ctDNA concentrations were lower in patients who achieved pathological complete response (pathCR) compared to patients with residual disease (median AFs, 0.003 and 0.017%, respectively, P = 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent.
- 7 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (504)
Top Cited PapersPersonalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 104 and 3 in 105, respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analyzed up to 115 mutations per patient in 80 plasma samples from 33 women with stage I to III breast cancer. Before treatment, TARDIS detected ctDNA in all patients with 0.11% median AF. After completion of neoadjuvant therapy, ctDNA concentrations were lower in patients who achieved pathological complete response (pathCR) compared to patients with residual disease (median AFs, 0.003 and 0.017%, respectively, P = 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent.
- 1 July 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (1) , 30-36e1
Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer
The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: dead of disease (DOD), dead of other cancers (DOC), and non-cancer death (NCD). The overall cumulative incidence of mortality was 4.9% for DOD, 3.7% for DOC, and 21.3% for NCD for the 47,220 patients studied. For all patients, the 5- and 8-year probability of DOD was 3% and 4.7%, for DOC 1.9% and 3.5%, and for NCD 9.8% and 18.9%, respectively. The presence of any major comorbidity (eg cardiovascular or neurologic disorders) significantly increased the probability of NCD, and estrogen receptor status was the strongest predictor of DOD. Given patient age, comorbidity, and estrogen receptor status, an estimate of competing risks of death from DOD, DOC, and NCD can be calculated. To aid clinical decision making, we quantify competing risks of death in patients with stage I breast cancer by taking into account patient age, comorbidity, and estrogen receptor status.
- 1 July 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (1) , 30-36e1
Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer
The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: dead of disease (DOD), dead of other cancers (DOC), and non-cancer death (NCD). The overall cumulative incidence of mortality was 4.9% for DOD, 3.7% for DOC, and 21.3% for NCD for the 47,220 patients studied. For all patients, the 5- and 8-year probability of DOD was 3% and 4.7%, for DOC 1.9% and 3.5%, and for NCD 9.8% and 18.9%, respectively. The presence of any major comorbidity (eg cardiovascular or neurologic disorders) significantly increased the probability of NCD, and estrogen receptor status was the strongest predictor of DOD. Given patient age, comorbidity, and estrogen receptor status, an estimate of competing risks of death from DOD, DOC, and NCD can be calculated. To aid clinical decision making, we quantify competing risks of death in patients with stage I breast cancer by taking into account patient age, comorbidity, and estrogen receptor status.